Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...
Specifically, I will discuss the acquisition of Dermavant Sciences Ltd., a Roivant Sciences Ltd. (ROIV) company, with a ...
Roivant Sciences Ltd (ROIV) showcases robust financial health with $5.4 billion in cash and no debt, while navigating competitive pressures and strategic opportunities.
Vivek Ramaswamy, 39, is a multimillionaire former biotech executive, who will lead the newly-established Department of ...
Indian-American entrepreneur and author Vivek Ramaswamy, known for founding Roivant Sciences, has become a prominent figure ...
Vivek Ramaswamy will lead, together with Elon Musk, the Department of Government Efficiency (D.O.G.E) in the Donald Trump ...
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...
BASEL, Switzerland - Roivant Sciences (NASDAQ:ROIV) announced the promising results of the Phase 1b ATMOS study for mosliciguat, a potential first-in-class inhaled therapy for... Roivant (Nasdaq ...
Good day and thank you for standing by. Welcome to the Roivant second-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback